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Abstract
The effects of antibiotic timing on outcomes of patients with community-acquired pneumonia (CAP) are controversial. Moreover, no
information is available regarding this issue in healthcare-associated pneumonia (HCAP). We aimed to determine the impact of antibiotic
timing on 30-day mortality of patients with CAP and HCAP. Non-immunocompromised adults admitted to hospital through the emer-
gency department (ED) with community-onset pneumonia were prospectively observed from 2001 to 2009. Patients who received prior
antibiotics were excluded. Of 1593 patients with pneumonia who were analyzed, 1274 had CAP and 319 HCAP. The mean time from
patient arrival at the ED until antibiotic administration was 5.8 h (standard deviation (SD) 3.5) in CAP and 6.1 h (SD 3.8) in HCAP
(p 0.30). Mortality was higher in patients with HCAP (5.5% vs. 13.5%; p <0.001). After adjusting for confounding factors in a logistic
regression analysis, the antibiotic administration £4 h was not associated with decreased 30-day mortality in patients with CAP (odds
ratio (OR) 1.12, 95% conﬁdence interval (CI) 0.57–2.21) and in patients with HCAP (OR 0.59, 95% CI 0.19–1.83). Similarly, antibiotic
administration £8 h was not associated with decreased 30-day mortality in CAP (OR 1.58, 95% CI 0.64–3.88) and HCAP patients (OR
0.59, 95% CI 0.19–1.83). In conclusion, antibiotic administration within 4 or 8 h of arrival at the ED did not improve 30-day survival in
hospitalized adults for CAP or HCAP.
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Introduction
Community-acquired pneumonia (CAP) continues to be an
important public health problem worldwide with a mortality
rate between 8% and 15% in hospitalized patients [1–3]. In
recent years there have been signiﬁcant changes in the man-
agement of CAP due to the availability of new diagnostic
tests, the publication of research that helps in selecting the
most appropriate initial site of care [4,5], and new recom-
mendations on the duration of antibiotic therapy [6]. Despite
these changes, however, mortality in patients with CAP
remains high and has barely improved since antimicrobials
were ﬁrst introduced in the 1940s [7].
The timing of the ﬁrst dose of antibiotics remains a con-
troversial point in the management of CAP. Although early
administration of appropriate treatment has been correlated
with a better prognosis in some infections [8], this relation-
ship is not clear in patients with CAP [9–19]. While some
studies do show a lower mortality with early administration
of antibiotics [10,13,15], the beneﬁt that would be expected
with early treatment can be offset by an increased misdiag-
nosis of CAP, an overuse of antibiotics and misprioritization
of patients [9,12,17,20]. Thus, although the 2003 IDSA guide-
lines recommended early treatment of CAP (£4 h) [21],
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more recent guidelines do not state a speciﬁc time window
for delivery of the ﬁrst antibiotic dose and merely suggest it
be given in the emergency department (ED) [6]. Similar rec-
ommendations have been reported in guidelines from other
geographical areas [20,22].
Healthcare-associated pneumonia (HCAP) has recently
been recognized as a new category of respiratory infection
that appears to merit a distinct approach to CAP [23–26].
The available data indicate that patients with HCAP are
older, have more comorbidities, are more likely to have
pneumonia caused by antibiotic-resistant organisms, and have
higher mortality [23–26]. At present, however, no informa-
tion is available regarding the effects of the timing of
antibiotic administration on outcomes in HCAP patients.
Thus, the current guidelines for the management of adult
patients with HCAP do not address this issue [27,28].
The present prospective study of a large cohort of hospi-
talized patients with community-onset pneumonia was car-
ried out to determine the impact of timing of antibiotic
administration on 30-day mortality of patients with CAP and
HCAP.
Materials and Methods
Setting, patients and study design
The study was performed in an 800-bed university hospital
for adults in Barcelona, serving an area of 900 000 inhabit-
ants. All non-immunocompromised patients hospitalized
through the emergency department (ED) with community-
onset pneumonia between 1 January 2001 and 31 October
2009 were analyzed. Cases were identiﬁed at the ED by the
attending physicians and/or study investigators. Data on all
patients were prospectively recorded using a computer-
assisted protocol. Patients who received prehospital antibiot-
ics were excluded. The study was approved by the hospital
Institutional Review Board and informed consent was
obtained from patients.
For the purpose of the present study, patients were
divided into two groups: patients with CAP and patients with
HCAP. Timing of antibiotic administration was measured in
hours and represented the difference between the time of
arrival at the ED and the recorded time of initial antibiotic
administration by nursing staff. Patients who received the
ﬁrst antibiotic dose within either 4 or 8 h of arrival at the
ED (two cut-off points, referred as to ‘early treatment’)
were compared with those who received antibiotics >4 or
>8 h after arrival at the ED (‘late treatment’). Four and eight
hours were chosen as the cut-off points so as to be consis-
tent with previous studies [10,13,15,18].
Clinical assessment and follow-up
At the initial visit and before starting empirical antibiotic
therapy, patients underwent a physical examination and a full
clinical history was taken. They were then seen daily during
their hospital stay by one or more of the investigators. Data
were collected on demographic characteristics, comorbidi-
ties, causative organisms, antibiotic susceptibilities, biochemi-
cal analysis, empirical antibiotic therapy and outcomes,
including 30-day mortality.
Two sets of blood samples were obtained and cultured
and, when available, a sputum sample was also evaluated by
use of Gram staining and culture. Urinary antigen detection
tests for Streptococcus pneumoniae and Legionella pneumophila
were performed if indicated by the attending physician.
Paired serum samples during the acute and convalescent
phases of infection (separated by a 3–8-week interval) were
also obtained for serological studies.
Antibiotic therapy was initiated in the emergency depart-
ment in accordance with the hospital guidelines, which rec-
ommend the administration of a b-lactam (ceftriaxone
sodium or amoxicillin/clavulanate potassium) with or without
macrolide or levoﬂoxacin. Combination therapy was recom-
mended for patients with clinical suspicion of a Legionella
species or an atypical pathogen, or in the absence of a
demonstrative ﬁnding on sputum Gram stain results. Levo-
ﬂoxacin was recommended for patients with a urine antigen
test result that was positive for L. pneumophila serogroup 1.
Combined amoxicillin/clavulanate was recommended for
patients with clinical suspicion of aspiration pneumonia.
Deﬁnitions
Pneumonia was deﬁned as an acute illness associated with
one or more of the following signs and symptoms: new
cough with or without sputum production, pleuritic chest
pain, dyspnea, fever or hypothermia, altered breath sounds
on auscultation, leukocytosis, and the presence of a new
inﬁltrate on a chest radiograph. HCAP included any patient
who fulﬁlled any of the following [23]: (i) received any home
health care, received intravenous therapy at home, received
wound care or specialized nursing care through a healthcare
agency, family or friends, or had self-administered intra-
venous medical therapy in the 30 days before pneumonia; (ii)
attended a hospital or haemodialysis clinic or received
intravenous chemotherapy in the 30 days before pneumonia;
(iii) were admitted to an acute care hospital for two or
more days in the 90 days before pneumonia; and (iv)
currently residing in a nursing home or long-term care facility.
Comorbidity was deﬁned as the presence of one of the
following previously diagnosed diseases: chronic lung disease,
chronic heart disease, chronic renal disease, chronic liver
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disease, chronic cognitive deﬁcit, cerebrovascular disease,
malignancy or diabetes mellitus. Patients in risk classes IV or
V of the Pneumonia Severity Index (PSI) were considered to
be more severely ill [5]. The diagnosis of septic shock was
based on the ACCP/SCCM Consensus Conference Commit-
tee [29]. Initial inappropriate empirical therapy was deﬁned
as the absence of antimicrobial therapy for a speciﬁc type of
organism or administration of an antibiotic to which the iso-
lated organism was resistant. The appropriateness of antibi-
otic therapy was analyzed for all cases with an aetiological
diagnosis according to susceptibility test criteria. Patients
with aspiration pneumonia who had not received anaerobic
coverage (i.e. amoxicillin-clavulanate) were considered to
have received inappropriate empirical antibiotic therapy.
Aspiration pneumonia was diagnosed as described elsewhere
[30].
The primary study outcome was 30-day mortality, deﬁned
as death due to any cause £30 days after hospitalization.
Mortality was ascertained by patients follow-up.
Statistical analysis
Time from arrival at the ED to antibacterial administration
was the independent variable. The characteristics of patients
who received early treatment were compared with those of
the late-treatment group. All proportions were calculated as
percentages of the patients with available data. To detect
signiﬁcant differences between groups, we used the chi-
square test or Fisher exact test for categorical variables and
the Student t-test or Mann–Whitney U-test for continuous
variables, as appropriate. The multivariate logistic regression
analysis of factors potentially associated with 30-day mortal-
ity included the clinical and signiﬁcant variables in the uni-
variate analysis and the timing of antibacterial administration
and inappropriate empirical antibiotic therapy, regardless of
whether the latter were signiﬁcant or not. We restricted
the number of variables included in the multivariable models
following the rule of at least ﬁve to nine events (deaths)
per variable [31]. The discriminatory power of the logistic
model was evaluated by the area under the receiver operat-
ing characteristic (ROC) curve and the goodness-of-ﬁt
according to the Hosmer–Lemeshow test. The analyses
were performed using SPSS (version 15.0, Chicago, IL,
USA). Statistical signiﬁcance was set at p <0.05. All reported
p values are two-tailed.
Results
Of the 1883 non-immunocompromised patients hospitalized
with community-onset pneumonia during the study period,
we excluded from the analyses those who had received pre-
hospital antibiotics (n = 290). The study sample comprised
the remaining 1593 patients, of whom 1274 (80%) had CAP
and 319 (20%) had HCAP. Overall, the mean time from
patient arrival at the ED until administration of the ﬁrst
dose of antibiotics was 5.9 h (standard deviation (SD)
3.6 h). Among study groups, the mean time from patient
arrival at the ED until antibiotic administration was 5.8 h
(SD 3.5) in CAP and 6.1 h (SD 3.8) in HCAP (p 0.30).
Eighty-six patients (27%) in the HCAP group had been
admitted to an acute care hospital for 2 or more days in
the 90 days before pneumonia; 139 (43.6%) attended a hos-
pital or a haemodialysis clinic or received intravenous che-
motherapy in the 30 days before pneumonia; 108 (33.9%)
resided in a nursing home or a long-term care facility; and
21 (6.6%) received home healthcare. A total of 113 (7.1%)
patients died within 30 days of hospitalization. The baseline
characteristics of patients with CAP and HCAP are detailed
in Table S1 (see description and table in the supplementary
online ﬁle).
When comparing patients who received early (£4 or
£8 h) antibiotic treatment with those who received late (>4
or >8 h) treatment there were no signiﬁcant differences in
the main demographic characteristics of the CAP and
HCAP groups (Tables 1 and S2). Regarding the clinical fea-
tures at admission, patients receiving early treatment
(mainly £4 h) had signiﬁcantly greater illness severity at
admission: they were more likely to present altered mental
status, septic shock and multilobar inﬁltrates on chest X-
ray. By contrast, there were no differences as regards aeti-
ology. In addition, patients with CAP who were given early
treatment (£4 h) were more likely to require intensive
care unit (ICU) admission and they also had higher 30-day
mortality.
Table 2 details the factors associated with 30-day mortal-
ity in patients with CAP and HCAP, respectively. Advanced
age, altered mental status, septic shock, bacteraemia and
high-risk PSI classes were more common in patients who
died in both pneumonia groups.
After adjustment for age, sex, comorbidities, initial inap-
propriate empirical therapy and illness severity, the timing of
the ﬁrst dose of antibiotics (4 or 8 h) had no impact on
mortality in CAP patients (Table 3). The p-value of the Hos-
mer–Lemeshow statistic for goodness-of-ﬁt was 0.45.
The multivariate logistic regression analysis for factors
associated with 30-day mortality in HCAP patients is shown
in Table 4. The timing of antibiotic administration (£4 and
£8 h) was not associated with decreased 30-day mortality in
patients with HCAP. The p-value of the Hosmer–Lemeshow
statistic for goodness-of-ﬁt was 0.28.
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Discussion
This prospective study of a large cohort of non-immunocom-
promised adult patients hospitalized with community-onset
pneumonia shows that antibiotic administration within 4 or
8 h of arrival at the ED did not improve 30-day survival in
hospitalized adults for CAP or HCAP.
Our ﬁnding that the timing of the ﬁrst dose of antibiotics
(£4 or £8 h) was not associated with 30-day mortality in
patients with CAP differs from the results reported by Hou-
ck et al. [15]. These investigators found that patients who
received early treatment (£4 h) had lower hospital mortality,
lower 30-day mortality and a shorter length of hospital stay.
However, it should be noted that this was a retrospective
study based on an analysis of medical records and discharge
TABLE 1. Characteristics of patients hospitalized for CAP and HCAP and classiﬁed into early and late treatment groups (£4
vs. >4 h)
Characteristics
CAP (n = 1274) HCAP (n = 319)
£4 h (n = 477) >4 h (n = 797) p £4 h (n = 116) >4 h (n = 203) p
Demographic features
Age (>64 years old) 271 (56.9) 466 (58.5) 0.56 89 (76.7) 155 (76.4) 0.94
Male sex 327 (68.6) 548 (68.8) 0.93 76 (65.5) 125 (61.6) 0.48
Underlying disease 343 (71.9) 584 (73.3) 0.59 112 (96.6) 182 (89.7) 0.02
Current/former smoker 265 (56) 481 (60.6) 0.11 64 (55.7) 105 (52.2) 0.55
Alcohol abuse 82 (17.3) 150 (18.9) 0.47 15 (13) 26 (12.9) 0.97
Seasonal inﬂuenza vaccination (<1 year) 210 (49.3) 328 (45.1) 0.17 67 (67.7) 111 (64.9) 0.64
Clinical features at hospital admission
Altered mental status 69 (14.5) 93 (11.7) 0.14 38 (33) 45 (22.2) 0.03
Septic shock 50 (10.5) 59 (7.4) 0.05 21 (18.3) 22 (10.8) 0.06
Multilobar pneumonia 173 (36.5) 245 (31.1) 0.04 49 (42.2) 64 (32) 0.06
Pleural effusion 77 (16.3) 143 (18) 0.42 14 (12.1) 35 (17.3) 0.21
Bacteraemia 65 (15.1) 99 (13.5) 0.43 12 (12.4) 26 (14.7) 0.59
High-risk PSI classesa 277 (58.2) 435 (54.7) 0.22 95 (81.9) 156 (76.8) 0.28
Aetiology
Streptococcus pneumoniae 209 (43.8) 315 (39.5) 0.13 40 (34.5) 74 (36.5) 0.72
Legionella pneumophila 38 (8.0) 57 (7.2) 0.59 1 (0.9) 7 (3.4) 0.15
Aspiration pneumonia 25 (5.2) 43 (5.4) 0.90 27 (23.3) 28 (13.8) 0.03
Initial antibiotic therapy
b-lactam monotherapy 191 (40) 331 (41.5) 0.60 61 (52.6) 106 (52.2) 0.94
Levoﬂoxacin monotherapy 78 (16.4) 158 (19.8) 0.12 8 (6.9) 20 (9.9) 0.36
Combination therapyb 202 (42.3) 37.5 (.08) 45 (38.8) 76 (37.4) 0.81
Inappropriate antibiotic therapy 18 (5.8) 29 (5.7) 0.99 8 (10.4) 13 (9.8) 0.90
Outcomes
ICU admission 64 (13.5) 64 (8.1) 0.002 11 (9.5) 12 (5.9) 0.23
30-day mortality 33 (6.9) 37 (4.6) 0.08 20 (17.2) 23 (11.3) 0.13
CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; ICU, intensive care unit. Data are presented as n (%).
aPatients were stratiﬁed into the following risk classes according to the PSI score: low risk (£90 points, classes I, II and III) and high risk (>90 points, classes IV and V).
bb-lactam plus levoﬂoxacin.
TABLE 2. Factors associated with 30-day mortality in hospitalized patients with CAP and HCAP: univariate analysis
Characteristics
CAP (n = 1274) HCAP (n = 319)
Alive (n = 1204) Death (n = 70) p Value Alive (n = 276) Death (n = 43) p Value
Demographic features
Age (>64 years old) 679 (56.4) 58 (82.9) <0.001 203 (73.6) 41 (95.3) 0.002
Male sex 826 (68.6) 49 (70) 0.80 174 (63) 27 (62.8) 0.97
Underlying disease 871 (72.3) 56 (80) 0.16 252 (91.3) 42 (97.7) 0.14
Current/former smoker 711 (59.3) 35 (51.5) 0.20 149 (54.4) 20 (47.6) 0.41
Alcohol abuse 224 (18.6) 8 (11.8) 0.15 39 (14.2) 2 (4.8) 0.08
Seasonal inﬂuenza vaccination (<1 year) 519 (46.6) 19 (47.5) 0.91 162 (67.2) 16 (55.2) 0.19
Clinical features at hospital admission
Altered mental status 138 (11.5) 24 (34.3) <0.001 59 (21.4) 24 (57.1) <0.001
Septic shock 85 (7.1) 24 (34.3) <0.001 32 (11.6) 11 (26.2) 0.01
Multilobar pneumonia 383 (32.1) 35 (51.5) 0.001 93 (34.1) 20 (46.5) 0.11
Pleural effusion 206 (17.2) 14 (20.6) 0.47 45 (16.4) 4 (9.3) 0.23
Bacteraemia 139 (12.6) 25 (37.9) <0.001 28 (11.7) 10 (28.6) 0.007
High-risk PSI classesa 645 (53.7) 67 (95.7) <0.001 209 (75.7) 42 (97.7) 0.001
Inappropriate antibiotic therapy 40 (5.2) 3 (5.5) 1 18 (10.1) 2 (6.5) 0.74
Timing of antibiotic administration
£4 h 444 (36.9) 33 (47.1) 0.08 96 (34.8) 20 (46.5) 0.13
£8 h 972 (80.7) 58 (82.9) 0.66 213 (77.2) 31 (72.1) 0.46
CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; PSI, pneumonia severity index. Data are presented as n (%).
aPatients were stratiﬁed into the following risk classes according to the PSI score: low risk (£90 points, classes I, II and III) and high risk (>90 points, classes IV and V).
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diagnoses, with the study population including patients from
a long-term care/skilled nursing setting and being limited to
patients aged 65 years. Furthermore, they found that patients
who received antibiotics in the ﬁrst 2 h died more frequently
than did those with later antibiotic administration, but it dis-
appeared under multivariate analysis. Interestingly, our
results similarly show that patients with CAP who received
early treatment (mainly £4 h) were more likely to require
ICU admission and had higher 30-day mortality. However,
these patients had more severe clinical features at hospital
admission (septic shock and multilobar pneumonia), which
indirectly indicates that in the ED context the more serious
patients are usually treated as a priority [12,16]. In addition,
Dedier et al. [32] and Cheng et al. [14] observed a strong
relationship between pneumonia severity on admission as
measured by the PSI, and earlier antibiotic administration.
Other studies have also found that lower 30-day mortality
[13] and shorter length of hospital stay [10] are associated
with antibiotic administration within 8 h of hospital arrival in
patients with pneumonia. However, these were also retro-
spective studies that included patients from a nursing home,
and one of them [13] was limited to patients aged 65 years.
Our results are, however, consistent with other published
studies [11,18,19]. Moreover, Yu and Wyer [18] conducted
a systematic review of 13 observational studies to assess the
impact of antibiotic timing on outcomes of patients with
CAP. They identiﬁed four groups of studies according to
their methodological quality (inclusion criteria, prospective
or retrospective design, exclusion of patients treated prior
to hospital admission and the use of a validated severity
score), but reported that evidence from observational stud-
ies fails to conﬁrm decreased mortality with early antibiotic
administration in stable patients with CAP.
Signiﬁcantly, previous studies evaluating the effect of delay
in the administration of antibiotics in patients with pneumo-
nia have not differentiated between CAP and HCAP
[10,13,15]. Thus, no information is available regarding the
effects of antibiotic timing on outcomes in patients with
HCAP. Therefore, the current guidelines for the manage-
ment of adult patients with HCAP do not address this point
[27,28]. Importantly, we did not ﬁnd signiﬁcant differences in
the mean time from patient arrival at the ED until antibiotic
administration between CAP and HCAP patients. However,
our results suggest that early administration of antibiotics
(£4 or £8 h) is not associated with a decrease in 30-day
mortality in HCAP patients. Interestingly, it was also recently
reported that guideline-concordant HCAP antibiotic therapy
was not associated with improved 30-day mortality for non-
critically-ill HCAP patients in the USA [33].
The strength of our study lies in the prospective collec-
tion of data from a large number of patients. In addition, we
performed a detailed evaluation of the clinical features of
patients with CAP and HCAP according to the time from
arrival at the ED to antibiotic administration. Similarly, to
our knowledge this is the ﬁrst study of its kind that includes
patients with HCAP. Finally, we controlled for confounding
factors related to mortality in our multivariate analysis. How-
ever, as the study is observational it is unable to avoid resid-
ual confounding. In this regard, we did not control for
patients with treatment limitations. In addition, sample size
calculation was not performed previous to the study. Simi-
larly, because of the relatively small sample size of patients
who died in HCAP patients, our data should be interpreted
with caution and need further validation.
In conclusion, antibiotic administration within 4 or 8 h of
arrival at the ED did not improve 30-day survival in hospital-
ized adults for CAP or HCAP.
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